Coloplast Sets FY27 Revenue Growth Outlook, Cuts Midterm Targets

MT Newswires · 1d ago
11:33 PM EST, 11/02/2026 (MT Newswires) -- Coloplast (COLO-B.CO) set its financial guidance for fiscal 2027 and lowered its midterm growth targets through fiscal 2030. For 2027, the Danish medical device company expects organic revenue growth of 5% to 7% and reported revenue growth of between 7% and 9%, according to a Monday filing. Coloplast also lowered its annual organic revenue growth target through fiscal 2030 to 5% to 7% from 7% to 8%, citing changes to US biologics reimbursement, healthcare pricing pressures, and inflation.